Kalydeco

Chemical Nameivacaftor
Dosage FormTablet (oral; 150 mg); Granules (oral; 25 mg, 50 mg, 75 mg)
Drug ClassCFTR potentiators
SystemRespiratory
CompanyVertex Pharmaceuticals
Approval Year2012

Indication

  • For the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kalydeco (ivacaftor) Prescribing Information.2012Vertex Pharmaceuticals Inc., Boston, MA